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Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease accompanied by a disturbed T-cell
balance skewed towards effector T-cells, in particular Th17-cells. The novel cytokine interleukin-21 (IL-21) is
suggested to be crucial for triggering T-cell responses towards IL-17 producing cells. Thus, we aimed to investigate
the ability of T-cells to produce IL-21 and IL-17 in SLE patients.
Methods: Peripheral blood of 34 SLE patients and 18 healthy controls (HC) was stimulated with phorbol myristate
acetate (PMA) and calcium ionophore (Ca-Io). Percentages of IL-21- and IL-17A expressing T-cells were analysed by
flow cytometry. The expression levels of the transcription factors B-cell lymphoma-6 (BCL-6) and factors retinoid-
related orphan receptor (ROR-gt) were assessed in T-cells by real-time RT-PCR and flow cytometry. Additionally, IL-
21 receptor (IL-21R) expression on B- and T-cells of patients and HC was analyzed.
Results: Significantly increased percentages of IL-21 expressing CD4
+ T-cells and CD8
+ T-cells were found in SLE
patients as compared to HC. The percentages of IL-21
+ CD4
+ T-cells and CD8
+ T-cells correlated significantly with
the percentages of IL-17A
+ CD4
+ T-cells and CD8
+ T-cells, respectively. The relative expression of BCL-6 and ROR-gt
did not differ between SLE patients and HC. IL-21R expression occurred mainly on B-cells and was not different
comparing SLE patients and HC.
Conclusions: This study demonstrates an increased proportion of IL-21
+ T-cells in SLE patients correlating with the
proportion of IL-17
+ T-cells. This suggests a pivotal role of IL-21 in the pathogenesis of SLE.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease of unknown etiology. The presence of antibodies
against dsDNA is a hallmark of SLE. Although the pre-
cise pathogenesis of SLE has not been fully elucidated,
disturbances in T-cell and B-cell homeostasis appear to
contribute to the inflammatory pathology of SLE. Sev-
eral cytokines have been demonstrated to be crucial for
the regulation of B- and T-cell homeostasis. Recently,
the novel cytokine interleukin (IL)-21 has been found to
play a pivotal role in differentiation and function of T-
cells. In particular, IL-21 drives an inflammatory T-cell
response by triggering the production of IL-17, which is
thought to be a crucial cytokine for inflammatory pro-
cesses as occur in lupus nephritis in SLE [1].
The novel class I cytokine IL-21 is a member of the
common g-chain receptor family. The production of IL-
21 is mainly restricted to CD4
+ T-cells, Th17- and T-
follicular helper (TFH)-cells. In addition, natural killer
(NK) T cells have been demonstrated to be potent IL-21
porducers in vitro [2]. High expression of the transcrip-
tion factors retinoid-related orphan receptor (ROR)-gt
and B-cell lymphoma-6 (BCL6) in T-cells is considered
to define specifically Th17- and TFH -cell lineages,
respectively. The unique IL-21 receptor (IL-21Ra)c a n
be expressed on various cell types, including T- and B-
cells, NK cells, dendritic cells and macrophages [3,4].
Ligation of IL-21 to its receptor IL-21Ra promotes B-
cell dependent IgG production, enhances expansion of
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+ cells and their cytotoxic capacity, and augments
naïve CD4
+ T-cell differentiation towards effector T-
cells [1,5,6].
Multiple murine models indicate a pivotal role of IL-
21 in the pathogenesis of autoimmune diseases [7-9]. In
an animal model of rheumatoid arthritis, blocking the
IL-21 pathway by administration of a fusion protein (IL-
21R.Fc) ameliorated disease severity [9]. In addition,
Fina et al. reported high levels of IL-21 in the inflamed
colon of wild-type mice, which developed colitis after
treatment with dextran sulfate sodium (DSS) as a model
of inflammatory bowel disease [8]. Further, they demon-
strated that IL-21 knockout mice were protected against
DSS induced inflammatory bowel disease [8]. The
authors suggested a reduced Th17 response in IL-21
deficient mice as an underlying mechanism which might
be beneficial in this murine model. Using a BXSB-Yaa
SLE murine model, it was demonstrated that mice
which are IL-21R-deficient show less lupus-like symp-
toms as compared to wild type BXSB-Yaa mice [7].
Human studies provide further evidence that the IL-
21/IL-21R pathway plays a major role in the pathogen-
esis of autoimmune diseases, in particular in SLE.
Plasma levels of IL-21 were significantly elevated in SLE
patients in comparison with healthy controls [10].
Sawalha et al. reported an association of two SNPs (sin-
gle nucleotide polymorphisms) located in the IL-21 gene
with SLE but functional data were not provided in this
study [11]. In general, functional data on IL-21 expres-
sion in human SLE and their potential link to IL-17A
producing effector T-cells are lacking so far.
Therefore, we aimed to elucidate the role of IL-21 in
the context of Th17-cells in the pathogenesis of human
SLE. We hypothesized that increased IL-21 production
is present in SLE patients. This might be correlated with
the Th17 response in SLE patients. In addition, the
study aimed to clarify whether Th17 cells are a source
of IL-21 in SLE patients. To investigate this, peripheral
whole blood was stimulated and the percentages of IL-
21 positive and Th17 positive T-cells were analysed.
Moreover, the expression of the transcription factors of
TFH- and Th17-cell specific messenger RNAs (mRNAs),
BCL6 and ROR-gt, respectively, was determined in iso-
lated unstimulated T-cells and stimulated T-cells. To
test whether B- and T-cells are susceptible for IL-21 sig-
nalling we analysed the proportion of IL-21R expressing
B- and T-cells in HC and SLE patients.
Materials and methods
Study population
Consecutive SLE patients (n = 34) aged 41 ± 15 mean
(± SD) years attending the outpatient clinic and 18 age-
and sex-matched healthy controls (age 39 ± 12 years)
were enrolled in this study. All patients fulfilled at least
four of the American College of Rheumatology’sr e v i s e d
criteria for SLE [12]. Disease activity was assessed by the
SLEDAI (SLE Disease Activity Index). Twenty-seven
patients had inactive disease (SLEDAI score ≤ 4) and
seven patients had active SLE (defined as SLEDAI score
> 4). Median disease activity for all patients was 4
(range 0 to 17). Four patients did not receive any
immuno-modulating medication at the time of analysis
(Table 1). Informed consent was obtained from patients
after approval of the study by the Medical Ethics Com-
mittee of the University Medical Center Groningen. The
study was conducted according to the ethical guidelines
of our institution and the Declaration of Helsinki.
Stimulation assay and immunofluorescent intracellular
staining for cytokines
Sodium heparinized venous blood was obtained from all
participants. Immediately after sampling, 200 μlb l o o d
was mixed with 200 μlR P M I 1 6 4 0( C a m b r e xB i o
Science, Verviers, Belgium), supplemented with 50 μg/
ml gentamycin (Gibco, Paisley, Scotland, UK), and
Table 1 Baseline characteristics and medication of SLE
patients (n = 34) and healthy controls (HC, n = 18)
included in the study.
SLE patients HC P-
value
Total number 34 18
Women/men 28/6 15/3 ns
Age (years, mean ± SD) 41 ± 14 35 ± 11 ns
SLEDAI (median (range)) 4 (0 to 17)
C3, g/l (median, range) 0.82 (0.37 to 1.45)
C4, g/l (median, range) 0.21 (0.04 to 0.30)
Anti-dsDNA, E/ml (median, range) 165 (4 to 1,000)
Treatment, n 18
None 4
Glucocorticoids, n 23
median dose (range), dose
(mg/day)
5 (3.75 to 60)
Immunosupressive/
immunmodulating, n
Hydroxychloroquine 17
median dose (range), users
(mg/day)
400 (200 to 600)
Methotrexate 2
median dose (range), users
(mg/week)
15 (5 to 25)
Azathioprine 12
median dose (range), users
(mg/day)
112.5 (50 to 150)
MMF 4
median dose (range), users
(mg/day)
2,500 (1,000 to
3,000)
SLEDAI: systemic lupus erythematosus disease activity index, MMF:
mycophenolate mofetil.
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ciences, Amsterdam, The Netherlands)) (400 μlp e r
tube). To determine the frequency of cytokine expres-
sing T-cell subsets, diluted blood was stimulated for 4 h
with 40 nM phorbol myristate acetate (PMA; Sigma-
Aldrich, Steinheim, Germany) and 2 nM calcium iono-
phore (Ca-Io; Sigma-Aldrich) in the presence of 3 μM
Brefeldine A. Brefeldine A was used to block intracellu-
lar transport mechanisms, thereby leading to an accu-
mulation of cytokines in the cell. As a negative control,
one sample remained without stimulation. Culture tubes
were incubated at 37°C, 5% CO2.
After stimulation, cells were incubated with 2.5 ml
amoniumchloride (pH 7.4) on ice. Lysed erythrocytes
were washed in wash buffer (PBS, 5% fetal bovine serum
(FBS), 0.1% sodium azide (Merck, Darmstadt, Germany))
and stained with PerCP- conjugated anti-CD8 (clone
SK1, BD Biosciences, Amsterdam, The Netherlands) and
allophycocyanin (APC)-conjugated anti-CD3 (clone
UCHT1, BD Biosciences), for 15 minutes at room tem-
perature. Cells were fixed with 100 μl Reagent A (Caltag
Laboratories, An der Grab, Austria) for 10 minutes.
After washing, the pellet was resuspended in 100 μl per-
meabilization Reagent B (Caltag Laboratories) and
labeled with Alexa Fluor 488-conjugated anti-IL17A
(clone eBio64Dec17) and PE-conjugated anti-IL21 (clone
ebio3A3-N2), (both purchased from eBioscience,
Uithoorn, The Netehrlands)), for 20 minutes in the
dark. After staining, the cells were washed and immedi-
ately analyzed on FACS-Calibur flow cytometer (BD
Biosciences).
Stimulation assay and immunofluorescent staining for
transcription factors
Peripheral blood mononuclear cells (PBMCs) from
patients and matched healthy controls were prepared
from heparinized venous blood by density-gradient cen-
trifugation on Lymphoprep (Axis-Shield PoC AS, Oslo,
Norway) immediately after blood was drawn. Cells
recovered from the gradient interface were washed twice
in PBS, adjusted to 1 × 10
7 cells/ml, and stimulated for
4 h with PMA and Ca-Io as aforementioned. After sti-
mulation, staining for BCL6 and ROR-gtw a sp e r f o r m e d
according to the manufacturer’s instructions
(eBioscience staining set for transcription factors).
Briefly, stimulated and unstimulated PBMCs were
adjusted to 1 × 10
7 cells in 100 μla n di n c u b a t e dw i t h
an appropriate concentration of eFluor450- conjugated
anti-CD3 (clone OKT3, eBioscience), and PerCP-conju-
gated anti-CD8 (clone SK1, BD Biosciences) for 30 min-
utes at 4°C in the dark, followed by fixation and
permeabilizaion in Fix/Perm buffer (eBioscience) for 45
minutes. Cells were then washed twice with 1 × permea-
bilization buffer (eBioscience), and stained with PE-
conjugated anti-BCL6 (clone 603406, R&D Systems,
Abingdon, UK)) and APC-conjugated anti-ROR-gt( c l o -
neAFKJS-9, eBioscience). After incubation for 30 min-
utes in the dark, the cell suspension was washed and
four-color staining was immediately analyzed on FACS-
LSRII flow cytometer (BD Biosciences).
Immunofluorescent surface staining for IL-21R on B- and
T- cells
Blood samples were labeled with the following monoclo-
nal antibodies: PE-conjugated anti-IL21R, APC-conju-
gated anti-CD3, PerCP-conjugated anti-CD4, FITC-
conjugated anti-CD19 (BD Biosciences, Amsterdam, The
Netherlands) for 15 minutes in the dark. Afterwards,
cells were successively treated with 2 ml diluted FACS
lysing solution (BD Biosciences) for 10 minutes and
then washed twice in wash-buffer and immediately ana-
lyzed by flow cytometry. Four-color staining was ana-
lyzed on FACS-Calibur (BD Biosciences).
Flow cytometric analysis
Four-color flow cytometric acquisition was performed
using Cell Quest software (Becton-Dickinson). For all
flow cytometric analyses, data were collected for 4 × 10
5
cells, and plotted using the Win-List software package
(Verity Software House Inc., Topsham, ME, USA).
Because stimulation reduces surface expression of CD4
on T-cells, CD4
+ T-cells were identified indirectly by
gating on CD3-positive and CD8-negative lymphocytes.
The unstimulated samples were used as a guide for set-
ting the linear gates to delineate positive and negative
populations for the cytokine production (Figure 1),
whereas appropriate isotype-matched controls were used
for setting the gates to quantify the percentage of T-
cells expressing a specific transcription factor.
Cell isolation and sorting of CD4
+ T-cells
Isolated PBMCs were frozen in RPMI 1640 (Cambrex
Bioscience, Verviers, Belgium) supplemented with 10%
fetal calf serum (FCS), 50 μg/ml of gentamicin (Gibco,
Paisley, UK) and 10% dimethylsulfoxide. PBMCs were
stored in liquid nitrogen. PMBCs were thawed gently
in 10% FCS supplemented RPMI 1640 medium at the
day of sorting. After washing, the cells were stained
with PerCP-conjugated anti-CD8 (clone SK1, BD Bios-
ciences) and allophycocyanin (APC)-conjugated anti-
CD3 (clone UCHT1, BD Biosciences), for 15 minutes
at room temperature and washed again. Sorting of
CD4
+ T-cells was performed by gating the CD3
+CD8
-
cell population.
RNA isolation and real-time RT-PCR
RNA was isolated from CD4
+ cells with TRIzol reagent
(Invitrogen, Bleiswijk, The Netherlands) according to
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(Ambion, Huntingdon, Cambridgeshire, UK) was per-
formed and subsequently cDNA was synthesized using
M-MLV reverse transcriptase and oligo (dT) 14 to 18.
For measurement of mRNA for BCL6 and ROR-gta n d
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 1
μl of cDNA in triplicate was used for amplification by
the Taqman RT-PCR system (ABI Prism 7900HT
Sequence Detection System, Applied Biosystems, Foster
City, CA, USA) with specific Taqman primers/probes
(Applied Biosystems). Amplification was performed
using standard conditions and calculations of fold
induction were performed. We normalized gene expres-
sion to GAPDH and expressed values relative to control
using the
ΔΔCT method.
Statistical analysis
Data are presented as mean ± SD unless stated other-
wise. The nonparametric Mann-Whitney U-test was
used to compare data between SLE patients and healthy
controls, and differences were considered statistically
significant at two-sided P-values less than 0.05. Paired
samples were analysed by Wilcoxon matched paired
test. Correlation analysis was performed using Spear-
man’s rank correlation coefficient.
Results
Increased percentages of IL-21
+ T-cells in SLE patients
In order to detect intracellular cytokine expression
whole blood was stimulated. Unstimulated T-cells of
SLE patients and HC did not spontaneously express IL-
21 or IL-17 (data not shown). Intracellular cytokine
expression was analysed after in vitro activation of CD4
+
T-cells and CD8
+ T-cells. Significantly increased percen-
tages of IL-21 expressing CD4
+ T-cells were found in
S L Ep a t i e n t sa sc o m p a r e dt oH C( 1 0 . 2±5 . 4 %v s .6 . 5±
3.5%, P = 0.007). Percentages of IL-21 expressing CD8
+
T-cells were also significantly increased in SLE patients
as compared to HC (3.9 ± 4.5% vs. 1.5 ± 1.1%, P = 0.01,
Figure 2A, B).
Figure 1 Increased IL-21 expression in T-cells of SLE patients. This figure shows a representative dot plot of cytokine expression in
unstimulated (A) and stimulated (B) blood samples. Due to the down-regulation of CD4 after stimulation with PMA/Ca-Io cells were gated for
CD3
+CD8
+ and CD3
+CD8
- T-cell subsets. Unstimulated samples were used as negative controls. The expression of IL-17A and IL-21 is shown for a
healthy control and an SLE patient.
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Figure 2 Multiparameter flow cytometric analysis of PMA/Ca-Io induced cytokine expression in CD4
+ T-cells and CD8
+ T-cells.W h o l e
blood from SLE patients and healthy controls (HC) was stimulated with PMA/Ca-Io and analyzed for intracellular cytokine expression of IL-21 and
IL-17A among CD4
+ T-cells and CD8
+ T-cells (A-F). Frequencies of these T-cells are shown. Horizontal lines represent the mean. P-values were
calculated using the nonparametric Mann-Whitney U-test.
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+ T-cells in active and inactive SLE
patients
To determine whether the intracellular IL-21 expression
was associated with disease activity we analyzed the pro-
portion of IL-21 producing T-cells in HC, active and
inactive SLE patients, respectively (Figure 2C). The per-
centages of IL-21 expressing cells within the CD4
+ T-
cell population were increased in inactive patients as
compared to HC (10.2 ± 5.8% vs. 6.5 ± 3.4%, P = 0.01).
Mean percentages of IL-21 expressing CD4
+ T-cells in
active patients were also significantly increased as com-
pared to HC (10.2 ± 3.4% vs. 6.5 ± 3.4%, P = 0.04), but
not higher than in inactive patients.
Percentages of IL-21 expressing cells within the CD8
+
T-cells were also increased in inactive patients as com-
pared to HC (4.0 ± 4.8% vs. 1.5 ± 1.2%, P = 0.03). There
was an increased proportion of IL-21 expressing CD8
+
T-cells in active SLE patients as compared to HC (3.8 ±
3.6% vs. 1.5 ± 1.1%, P = 0.04, Figure 2D). Additionally,
there was no correlation between the percentages of IL-
21 expressing cells within the CD4
+ or CD8
+ T-cell
population and SLE disease activity index (r = 0.15, P =
0.39 and r = 0.14, P = 0.45, respectively). Also, no corre-
lation was present between percentages of IL-21 expres-
sing cells within the CD4
+ or CD8
+ T-cell population
and complement levels (C3 and C4) or anti-dsDNA
autoantibody-titres (data not shown).
In order to assess the influence of treatment on the
proportion of IL-21 expressing CD4
+ T-cells we per-
formed a subanalysis comparing patients without medi-
cation or on prednisolone only (n = 8) with patients on
a combination of immunosuppressives (n =2 6 ) .T h e r e
was no significant difference in the proportion of IL-21
expressing CD4
+-a n dC D 8
+ T-cells between these
groups (8.2 ± 4.6% vs. 10.4 ± 5.7%, n.s. and 3.1 ± 2.9%
vs. 4.2 ± 4.9% n.s.).
Percentages of IL-21
+ T-cells correlate with percentages
of IL-17A
+ T-cells
In order to analyze the relation between IL-21
+ T-cells
and IL-17A
+ T-cells, we correlated percentages of IL-21
+ T-cells with percentages of IL-17A
+ T-cells in SLE
patients and HC. Interestingly, there was a significant
correlation between percentages of CD4
+IL-21
+ -T-cells
and CD4
+IL-17A
+ T-cells in SLE patients (r = 0.55, P =
0.0006) (Figure 2E). Also, a significant correlation was
found between percentages of CD8
+IL-21
+ -T-cells and
CD8
+IL-17A
+ T-cells in SLE patients (r = 0.5, P =
0.0003) (Figure 2F).
Proportions of IL-21R expressing cells are highest within
CD19
+ B-cells in SLE patients and HC
An altered IL-21/IL21R signalling might also be
explained by different levels of IL-21R expression.
Therefore, the expression of IL-21R on B- and T-cells
was analysed as well (Figure 3). There was no difference
in IL-21R expression on CD19
+,C D 4
+ and CD8
+ cells
between SLE patients (n = 14) and HC (n =6 ) .T h e
highest proportions of IL-21R expressing cells were
found in the CD19
+ B-cell subset. In SLE patients, 48.9
± 25.0% of CD19
+ B - c e l l sw e r ee x p r e s s i n gt h eI L - 2 1 R
vs. 62.2 ± 12.0% in HC (P = 0.34). Percentages of CD4
+
T-cells expressing the IL-21R were 28.3 ± 18.1% in SLE
patients as compared to 29.4 ± 15.6% in HC (P = 0.53).
Percentages of CD8
+ T-cells expressing the IL-21R were
31.9 ± 19.0% in SLE patients as compared to 29.0 ±
12.5% in HC (P = 0.53).
Relative expression of BCL6 and ROR-gt is not altered in
SLE
To test whether TFH- and Th17 specific transcription
factor expression is altered in SLE, RNA was isolated
from sorted CD4
+ T-cells of SLE patients (n =7 )a n d
HC (n = 4) (Figure 4A, B). The relative expression of
CD2 mRNA served as a positive control. The expression
levels were not different between SLE patients and HC
(0.337 ± 0.152 vs. 0.267 ± 0.066). The relative expression
of BCL6 was 0.003 ± 0.004 in CD4
+ T-cells of SLE
patients as compared to 0.02 ± 0.02 in HC (P = 0.07).
The relative expression of ROR-gt was low and also not
significantly different between SLE patients and HC
(0.007 ± 0.007 vs. 0.01 ± 0.004, P = 0.3).
Percentages of BCL6
+ and ROR-gt
+ CD4
+ T-cells do not
differ between unstimulated and stimulated conditions
Next, the expression of the transcription factors BCL6
and ROR-gt were assessed in CD4
+ T-cells, in both
unstimulated and stimulated samples, by flow cytometry.
The percentages of ROR-gt
+ in unstimulated CD4
+ T-
cells of SLE patients (n =4 )w e r e3 . 8±1 . 4 %v s .2 . 0±
0.8% (n.s.) (Figure 4). There was also no significant dif-
ference in the proportion of BCL6
+ CD4
+ T-cells of SLE
patients after stimulation with PMA and Ca-Io (14.0 ±
6.7% vs. 8.2 ± 4.3%, n.s.). Furthermore, the analysis of
healthy controls (n = 4) revealed no significant differ-
ence of the percentages of ROR-gt
+ CD4
+ T-cells or
BCL6
+ CD4
+ T-cells after stimulation, respectively.
(ROR-gt
+: 2.6 ± 1.4% vs. 0.4 ± 0.2% and BCL6
+:6 . 6±
3.9% vs. 5.9 ± 3.0%). There was also no significant dif-
ference between the percentages of BCL6
+ and ROR-gt
+
cells among the CD8
+ T-cells in SLE patients and
healthy controls (data not shown).
Discussion
The present study is the first demonstrating increased
proportions of IL-21
+ T-cells in SLE patients in compar-
ison with HC. Increased proportions of IL-21
+ cells
could be observed in both CD4
+ and CD8
+ T-cells.
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Page 6 of 10The IL-21/IL-21R pathway seems to play an important
role in the homeostasis of T-cells, in particular in the
differentiation of naïve T-cells towards Th17 cells.
These cells have been identified to be key mediators in
autoimmune diseases such as SLE [13-15]. Additionally,
Th17 cells have been shown to be a source of IL-21
[16]. It is likely that IL-21 induces CD4
+ T-cells to pro-
duce IL-17 and that IL-17 amplifies the effector
response via an autocrine loop [17]. To elucidate
whether Th17 cells in SLE are a source of IL-21 we ana-
lyzed the proportion of IL-21
+ T-cells in combination
with IL-17
+ T - c e l l s .A l m o s tn oI L - 2 1
+ IL-17
+ double
positive cells were detectable in SLE patients and HC
upon stimulation with PMA/Ca-Io. This indicates that
mainly other T-cells, such as T-follicular helper cells
(TFH), are the source of this cytokine [18]. Although the
relative expression of BCL6, the master regulator of
TFH, was not increased in unstimulated T-cells of SLE
patients in comparison with HC, other studies suggest
that TFH are the main source of IL-21 [19]. A study by
Simpson et al. has shown that BCL6 expression is rela-
tively low in all peripheral T-cell subsets in comparison
to tonsillar TFH [20]. Remarkably, in mice the number
of circulating TFH is independent of circulating serum
D
Figure 3 Expression of IL-21R on B- and T-cells of SLE patients. The histograms show a representative example of the expression of IL-21R
on CD19
+-cells (A), CD4
+-cells (B) and CD8
+-cells (C). Positive staining (red line) was compared to an isotype control (grey line). The proportion
of receptor positive cells is indicated. D shows the IL-21R expression on CD19
+ B-cells and CD4
+ and CD8
+ T-cells from SLE patients (n = 14) in
comparison with healthy controls (HC, n = 6). Horizontal lines represent the mean. P-values were calculated using the nonparametric Mann-
Whitney U-test.
Dolff et al. Arthritis Research & Therapy 2011, 13:R157
http://arthritis-research.com/content/13/5/R157
Page 7 of 10IL-21. This might be different in humans. In the present
study, we showed that the expression level of BCL6 in
sorted T-cells from peripheral blood of SLE patients and
HCs was relatively low. This is in line with the findings
of Simpson et al. Remarkably, the proportion of BCL6
expression in CD4
+ T cells, analyzed by flow cytometry
method, tended to be higher in SLE patients; however,
this did not reach significance. In addition, the propor-
tion of BCL6
+CD4
+ T-cells and ROR-gt
+CD4
+ T-cells in
unstimulated samples were in agreement with those of
the in vitro induced cytokine expression of IL-21 and
IL-17, respectively.
We found a strong positive correlation between per-
centages of IL-21
+ CD4
+ T-cells and percentages of IL-
17
+ CD4
+ T-cells in SLE patients. The same correlation
was found for CD8
+ T-cells. In line with these results a
similar correlation between IL-21
+ CD4
+ T-cells and
Th17 cells has been reported in patients with autoim-
mune thrombocytopenia (ITP) [21]. However, the pro-
portion of IL-17 producing T-cells was not significantly
increased in SLE patients compared to HC. This was
probably due to the low numbers of patients included.
Furthermore, recently it has been shown that IL-21 in
the presence of IL-6, (which is increased in part of the
SLE patients as well), promotes differentiation towards
Tfh cells instead of towards Th-17 cells [22,23].
Subanalysis of the proportions of IL-21
+ T-cells
revealed no difference between active and inactive dis-
ease. Moreover, there was no correlation between pro-
portions of IL-21
+ T-cells and the SLE Disease Activity
Index (SLEDAI). Although this could be due to the rela-
tively small group of active patients who were enrolled,
an intrinsic abnormality is possible as well. We did not
find an influence of treatment on the proportion of IL-
21
+ T-cells in SLE.
T- and B-cells have been reported to be targets of IL-
21. IL-21 influences immunoglobulin production and
promotes B-cell expansion and plasma cell generation
[5,24]. T-cell dependent autoantibody production might
also be regulated by IL-21. The comparable expression
of IL-21R on T-cells between SLE patients and HC sug-
gests that patients have the same abilitiy to respond to
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Figure 4 Relative expression of transcription factors BCL6 and ROR-y. The relative mRNA expression of BCL6 and ROR-y in unstimulated,
sorted CD4
+ T-cells was determined in SLE patients (SLE, n = 7) and healthy controls (HC, n =4 )( A/B). There was no significant difference in
the relative expression between these two groups. Bars represent the mean values ± SD. In (C) a representative dot plot of unstimulated and
stimulated PBMCs from a SLE patient a healthy control is shown. The percentages of BCL6 and ROR- gt
+ CD4
+ T-cells in unstimulated (dots) and
stimulated samples (squares) are given (D).
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Page 8 of 10IL-21 as HC. The high percentage of B-cells expressing
IL-21R in the present study encourages the idea that the
IL-21/IL-21R pathway might be important for B-cell
function. A study by Mitoma et al. reported that mainly
naive B-cells express the IL21R but also memory B-cells
and plasmablasts [25]. In contrast to our results, the
authors found significantly lower levels in SLE patients
in comparsion with HC. First, this might be explained
by differences in staining procedures. Secondly, differ-
ences in clinical characteristics might have influenced
the results, but clinical characteristics were not
described in the paper by Mitoma et al. [25].
Additionally, increased IL-21 plasma levels have been
found in SLE patients [10]. Therefore, we tested whether
there was a correlation between percentages of IL-21
+CD4
+ T-cells and anti-dsDNA titres. However, there
was no correlation between these variables. This is likely
due to the fact that anti-dsDNA production in vivo is
complex and dependent on co-stimulation, various cyto-
kines and soluble factors. The percentages of circulating
plasma cells as a source of anti-dsDNA antibodies might
be associated with titres but were not analysed.
IL-21
+ seems to regulate the suppressive capacity of
T-cells through the inhibition of Treg function and on
the other hand to amplify effector T-cells by promoting
the Th17 response [8,26]. In the present study, we
demonstrate an increased proportion of IL-21
+ T-cells,
which correlate with the proportion of IL-17
+ T-cells in
SLE. Thus, IL-21
+ T-cells might contribute to the gen-
eration of pathogenic T-cells in this autoimmune dis-
ease. Blocking the IL-21/IL-21R pathway by
administration of a fusion protein has been fruitful in
animal models of RA and in a lupus-prone MRL-Fas
lpr
mouse model [8,27]. Treatment with IL-21R.Fc reduced
renal disease, skin lesions and circulating auto-antibo-
dies in these MRL-Fas
lpr mice. Remarkably, CD4
+ and
CD8
+ T-cells in the spleen of these mice were reduced
after treatment with IL-21R.Fc supporting the idea that
IL-21 has also a major impact on T-cell populations.
Conclusions
In conclusion, this study demonstrates increased pro-
portions of IL-21
+ T-cells in SLE patients, which were
correlated with proportions of IL-17
+ T-cells. Inhibiting
the IL-21/IL-21R pathway has been shown to be effec-
tive in ameliorating disease severity in lupus mouse
models. Targeting IL-21 in human SLE could be a pro-
mising approach in the future [28]. Therefore, further
investigations are necessary to confirm and extend the
current results.
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